P 9. The effects of transrectal radiofrequency hyperthermia on patients with chronic prostatitis and the changes of MDA, NO, SOD and Zn levels in pretreatment and post-treatment

Obiective: To assess the effect of transrectal radiofrequency hyperthermia (TRFH) in 159 patients suffering from chronic prostatitis (CP), and explore the changes of reactive oxygen species in CP patients pre-treatment and post-treatment.

Methods: Patients diagnosed with chronic prostatitis were randomized to 6 weeks of tamsulosin plus clarithromycin, TRFH or TRFH with tamsulosin plus clarithromycin group,respectively. The primary outcome measure was evaluated by the National Institutes of Health Chronic Prostatitis Symptom Index. Malondiadehyde (MDA), superoxide dismutase (SOD), and nitrogen monoxide (NO) were measured by biochemical assay. Zinc content was assayed by atomical spectrophotography.

Results: All 105 patients in the TRFH or TRFH with tamsulosin plus clarithromycin group showed statistically significant improvement of pain, QoL, and micturition domains in comparison to the tamsulosin plus clarithromycin group, and regardless of type IIIa or type IIIb CP, there was a significant improvement in the TRFH or TRFH with tamsulosin plus clarithromycin compared to tamsulosin plus clarithromycin group (P<0.05). Compared with pre-treatment, MDA, NO and zinc were decreased in type II and IIIa, while SOD were only increased significantly in type II (P<0.05 ).

Conclusions: Our study reveal TRFH as a effective therapy option for CP, especially type IIIa or type IIIb CP. The effects of TRFH with tamsulosin plus clarithromycin group is superior to the TRFH group or the tamsulosin plus clarithromycin group alone. Comparison with pre-treatment, differences in ROS levels in CP patients suggest that these factors could be used as a biomarker to evaluate the symptoms of CP and the effects of treatment.